Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.

Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.

Future Oncol. 2019 Feb 13;:

Authors: Morrison VA, Shou Y, Bell JA, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Eaddy M, Galaznik A

Abstract
AIM: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL).
PATIENTS & METHODS: First-line and relapsed/refractory treatment patterns and survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated.
RESULTS: A total of 1436 DLBCL patients initiated treatment and mainly received a combination regimen versus monotherapy (92.1 vs 7.9%). Patients who received monotherapy were older with more comorbidities and had shorter progression-free survival than patients receiving combination therapy (median, 31.3 vs 55.8 months). In the second-line setting (n = 164), rituximab-based combination regimens were most common; 25% underwent stem cell transplantation, and were younger with fewer comorbidities.
CONCLUSION: These results illustrate the need for new treatment options for patients unable to tolerate initial combination therapy and transplant-ineligible patients who require salvage therapy.

PMID: 30757910 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2SxC4rV